Welcome to our dedicated page for Masimo news (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo stock.
Masimo Corporation (NASDAQ: MASI) is a global medical technology company focused on noninvasive patient monitoring, sensors, patient monitors, and automation and connectivity solutions. The Masimo news feed on Stock Titan aggregates company announcements, financial updates, clinical study results, and other material developments that the company discloses through press releases and regulatory communications.
Investors and observers can find news on Masimo e2 80 99s quarterly and annual financial results, including GAAP and non-GAAP revenue, earnings per diluted share, and constant currency revenue growth, as reported in earnings releases and related Form 8-K filings. These updates often include commentary from management on the performance of the healthcare business, operating efficiency initiatives, and guidance for future periods.
Masimo news also covers strategic and corporate actions, such as the completion of the sale of its consumer audio business, Sound United, to Harman International Industries, Incorporated, as disclosed in a September 23, 2025 Form 8-K and related press release. Additional items may include announcements about investor days, participation in healthcare conferences, and updates on long-range financial targets and growth pillars.
Given Masimo e2 80 99s emphasis on clinical evidence and intellectual property, the news flow features results from clinical and feasibility studies involving Masimo SET ae pulse oximetry, including research on performance across different skin tones and in critically ill patients. It also includes statements on significant legal outcomes, such as jury verdicts in patent infringement cases related to Masimo e2 80 99s technologies. By following this page, readers can monitor how Masimo communicates its financial performance, strategic focus on healthcare monitoring, and developments in clinical validation and intellectual property protection.
Masimo Corporation (Nasdaq: MASI) announced preliminary financial results for Q3 2020, projecting product revenue between $274 million and $278 million, representing a growth of 19.7% to 21.4% year-over-year. For the full year 2020, Masimo expects product revenue to be between $1,124 million and $1,128 million, reflecting a growth of 20.0% to 20.5% compared to 2019. A conference call is scheduled for October 27, 2020, to discuss complete financial results and guidance.
Masimo (NASDAQ: MASI) has launched the Radius Tº™ Continuous Thermometer, a wearable device that continuously monitors body temperature and sends data to a smartphone app. This innovation aims to enhance patient care by providing real-time temperature trends without interrupting daily activities, such as sleep. The Radius Tº sensor offers laboratory-accurate measurements within ±0.1ºC and is designed for use in various age groups. While not FDA 510(k) cleared, it is CE marked and marketed under the FDA’s COVID-19 enforcement policy.
Masimo (NASDAQ: MASI) has received FDA clearance for its new Rad-G Pulse Oximeter, a portable device that offers advanced pulse oximetry and vital sign monitoring capabilities. This handheld device is designed for both adults and children, featuring a long-lasting rechargeable battery and a direct-connect sensor. With a robust design, the Rad-G is suitable for varied environments, including outpatient services and emergency scenarios. The device includes continuous monitoring capabilities and is powered by Masimo's proven SET technology, widely used in hospitals for accurate patient assessments.